Endogenous Myc maintains the tumor microenvironment.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Myc deregulation is common in human cancers, presenting it as a potential therapeutic target.
• Previous studies demonstrated Myc inhibition's efficacy in Ras-driven lung tumors, leading to tumor regression.
• The precise therapeutic mechanisms and broader applicability of Myc inhibition across different cancer types remain unclear.

Purpose of the Study:

• To investigate the therapeutic effects of inhibiting endogenous Myc in a simian virus 40 (SV40)-driven pancreatic islet tumor model.
• To elucidate the underlying mechanisms of Myc inhibition-induced tumor regression.
• To assess the role of Myc in connecting oncogenic pathways to the tumor microenvironment.

Main Methods:

• Utilized a simian virus 40 (SV40)-driven pancreatic islet tumor model in preclinical studies.
• Administered targeted inhibition of endogenous Myc.
• Monitored tumor regression, tumor microenvironment changes, and tumor vasculature involution.

Main Results:

• Inhibition of endogenous Myc led to widespread regression of pancreatic islet tumors.
• Tumor regression was preceded by the collapse of the tumor microenvironment.
• Involution of tumor vasculature was observed concurrently with tumor regression.

Conclusions:

• Endogenous Myc plays a critical and non-redundant role in linking various intracellular oncogenic pathways to the tumor microenvironment.
• Myc inhibition demonstrates therapeutic potential beyond Ras-driven lung cancers, including in pancreatic cancer.
• These findings strengthen the rationale for targeting Myc pharmacologically across diverse cancer types.